Ranbaxy gets US nod to sell Alzheimer's generic

Ranbaxy may get the final FDA approval to market the drug known under the brand name, Aricept, as soon as patent protection over the drug expires on November 25.Aricept raked in sales of about $3.2 billion globally last fiscal, 60% of which came from the US, the world’s largest pharmaceutical market. 

The exclusivity status was confirmed by the US regulator, the Food and Drug Administration (FDA), after it dismissed Israeli drug major Teva’s claim for a shared marketing exclusivity for the drug. The drug will fetch Ranbaxy about $300 million (Rs 1,370 crore) during the exclusivity period.